Using Oliceridine to Reduce Nausea After Colorectal Surgery
Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting in Laparoscopic Colorectal Surgery: A Randomized Trial
This study is testing if a new pain medication called oliceridine can help reduce nausea and vomiting after laparoscopic colorectal surgery compared to traditional morphine.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 252 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06411665 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of oliceridine, a novel selective μ-opioid agonist, in reducing postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic colorectal surgery. The study compares oliceridine with traditional morphine for patient-controlled analgesia, aiming to determine if oliceridine can provide effective pain relief with fewer side effects related to nausea. By focusing on the mechanisms of opioid action, particularly the G protein-biased signaling, the trial seeks to improve recovery outcomes for patients. The randomized design ensures a robust evaluation of the intervention's impact on PONV incidence.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 scheduled for elective laparoscopic colorectal surgery who require patient-controlled intravenous analgesia.
Not a fit: Patients with severe heart dysfunction, hepatic or renal insufficiency, or those unable to complete preoperative assessments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of postoperative nausea and vomiting, leading to faster recovery and improved patient satisfaction.
How similar studies have performed: Previous studies have shown that oliceridine is effective in managing pain with fewer adverse effects in other surgical contexts, suggesting potential success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged between 18 and 80 years; 2. Scheduled to undergo elective laparoscopic colorectal surgery; 3. Required patient-controlled intravenous analgesia. Exclusion Criteria: 1. Pregnancy. 2. Severe heart dysfunction (New York Heart Association functional classification 4), hepatic insufficiency (Child-Pugh grade C), renal insufficiency (serum creatinine of 442 μmol/L or above, or requirement of renal replacement therapy), or Amercian Society of Anesthesiologists classification IV or above. 3. Unable to complete preoperative assessment due to severe dementia or language barrier. 4. Other conditions that are considered unsuitable for study participation.
Where this trial is running
Beijing
- Dong-Xin Wang — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Xue Li, M.D.
- Email: 3999165@163.com
- Phone: +8618810527114
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.